Expert perspectives on the use of frontline BTKi (Bruton's tyrosine kinase inhibitors) monotherapy in the treatment of chronic lymphocytic leukemia (CLL).
EP. 1: Approved BTKi Frontline Treatments for CLL
Jennifer R. Brown, MD, PhD, highlights newly FDA approved Bruton’s tyrosine kinase inhibitor (BTKi) monotherapy therapies for the treatment of CLL (chronic lymphocytic leukemia).
EP. 2: Tolerability of Ibrutinib, Zanubrutinib, and Acalabrutinib
Citing results from recent trials, Jennifer R. Brown, MD, PhD, compares patient tolerability levels of ibrutinib, zanubrutinib, and acalabrutinib.
EP. 3: Advice for Ibrutinib-Intolerant Patients
Jennifer R. Brown, MD, PhD, suggests alternative treatments for patients who experience severe adverse-events from ibrutinib.
EP. 4: Unmet Needs in Frontline Treatment of CLL
The shortcomings physicians face in combatting CLL (chronic lymphocytic leukemia) are discussed, in addition to what the high-level updates from the ELEVATE-RR press release may reveal regarding future treatments for CLL.
2 Clarke Drive Cranbury, NJ 08512